Protagonist Therapeutics (PTGX) Profit After Tax (2015 - 2026)
Protagonist Therapeutics (PTGX) reported Profit After Tax of $3.8 million for Q1 2026, up 132.46% on a YoY basis from $1.6 million in Q1 2025, and up 108.52% sequentially from -$44.4 million in Q4 2025.
Protagonist Therapeutics (PTGX) Profit After Tax (2015 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 12 years of Profit After Tax data on file, last reported at $3.8 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax rose 132.46% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at -$114.7 million (down 304.14% YoY), and the FY2025 full-year result was -$130.1 million, down 147.29% from the prior year.
- Profit After Tax improved to $3.8 million in Q1 2026, from -$44.4 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of $207.3 million in Q1 2024 to a low of -$44.4 million in Q4 2025.
- A 5-year average of -$3.4 million and a median of -$33.2 million in 2024 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax jumped 714.8% in 2024 and plunged 133.71% in 2025, its largest moves.
- Tracing PTGX's Profit After Tax over 5 years: stood at -$34.2 million in 2022, then surged by 179.94% to $27.3 million in 2023, then soared by 381.7% to $131.7 million in 2024, then sank by 133.71% to -$44.4 million in 2025, then surged by 108.52% to $3.8 million in 2026.
- Business Quant data shows PTGX's Profit After Tax at $3.8 million in Q1 2026, -$44.4 million in Q4 2025, and -$39.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Protagonist Therapeutics | 8.88 Bn | 8.88 Bn | - | 3.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.78 Mn |
| Dec 31, 2025 | -44.38 Mn |
| Sep 30, 2025 | -39.34 Mn |
| Jun 30, 2025 | -34.77 Mn |
| Mar 31, 2025 | -11.66 Mn |
| Dec 31, 2024 | 131.67 Mn |
| Sep 30, 2024 | -33.21 Mn |
| Jun 30, 2024 | -30.62 Mn |
| Mar 31, 2024 | 207.34 Mn |
| Dec 31, 2023 | 27.34 Mn |
| Sep 30, 2023 | -34.11 Mn |
| Jun 30, 2023 | -38.46 Mn |
| Mar 31, 2023 | -33.73 Mn |
| Dec 31, 2022 | -34.19 Mn |
| Sep 30, 2022 | -31.23 Mn |
| Jun 30, 2022 | -41.04 Mn |
| Mar 31, 2022 | -20.93 Mn |
| Dec 31, 2021 | -36.91 Mn |
| Sep 30, 2021 | -33.80 Mn |
| Jun 30, 2021 | -30.84 Mn |